| Role of DNA methyltransferase 1 in hormone-resistant prostate cancer. | |
| | |
MedLine Citation:
|
PMID: 20544341 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Given the poor outcome of patients with hormone-resistant (HR) prostate cancer, new strategies are needed to improve the current therapeutic regimens and/or develop novel treatments. We therefore aimed to provide a better understanding of the molecular mechanisms involved in the aggressive tumor behavior of HR and develop more rational anti-tumor therapies. Three HR prostate cancer cell lines (androgen receptor (AR)-positive LNCaP-HR and 22RV1-HR and AR-negative PC-3) were used. Changes in tumor behavior, treatment response, and related signaling in HR were investigated in vitro and in vivo. The results revealed that constitutional activation of STAT3 and overexpressions of DNMT1 were important in the transition of HR prostate cancer. Furthermore, DNMT1 expression was required for the maintenance of STAT3 activation. When DNMT1 activity in HR was blocked, aggressive tumor behavior and treatment resistance could be overcome, which was seen in both in vitro and in vivo experiments. The underlying changes associated with inhibited DNMT1 included less epithelial-mesenchymal changes, less invasion ability, slower tumor growth, and impaired DNA repair ability, which are independent of AR and p53 status. In conclusion, altered DNMT1 expression associated with activated STAT3 may be crucial in the transition of HR. Targeting DNMT1 could be a promising strategy for the treatment of HR prostate, as evidenced by inhibited tumor growth and enhanced radiosensitivity. These findings provide evidence for therapeutically targeting DNMT1 in HR prostate cancer. |
| | |
Authors:
|
Miao-Fen Chen; Wen-Cheng Chen; Yu-Jia Chang; Ching-Fang Wu; Chun-Te Wu |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2010-06-12 |
Journal Detail:
|
Title: Journal of molecular medicine (Berlin, Germany) Volume: 88 ISSN: 1432-1440 ISO Abbreviation: J. Mol. Med. Publication Date: 2010 Sep |
Date Detail:
|
Created Date: 2010-08-13 Completed Date: 2011-02-17 Revised Date: 2011-07-08 |
Medline Journal Info:
|
Nlm Unique ID: 9504370 Medline TA: J Mol Med (Berl) Country: Germany |
Other Details:
|
Languages: eng Pagination: 953-62 Citation Subset: IM |
Affiliation:
|
Department of Radiation Oncology, Chang Gung Memorial Hospital, Taipei, Taiwan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Cell Line, Tumor DNA (Cytosine-5-)-Methyltransferase / metabolism* Humans Male Mice Mice, Nude Neoplasms, Hormone-Dependent / metabolism, pathology Prostatic Neoplasms / enzymology*, etiology, metabolism, pathology Receptors, Androgen / metabolism STAT Transcription Factors / metabolism Time Factors |
| Chemical | |
Reg. No./Substance:
|
0/AR protein, human; 0/Receptors, Androgen; 0/STAT Transcription Factors; EC 2.1.1.37/DNA (Cytosine-5-)-Methyltransferase; EC 2.1.1.37/DNA (cytosine-5-)-methyltransferase 1 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The regulation of class IA PI 3-kinases by inter-subunit interactions.
Next Document: Do repetitive Valsalva maneuvers change maximum prolapse on dynamic MRI?